Immuron (IMRN) Long-Term Deferred Tax (2017 - 2023)

Immuron (IMRN) posted quarterly Long-Term Deferred Tax of $2.0 million for Q3 2023, up 7433.67% quarter-over-quarter from -$27920.0 in Q3 2023.

Immuron (IMRN) Long-Term Deferred Tax (2017 - 2023) Analysis & Trends

Immuron's Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $2.0 million for Q3 2023.

In Q3 2023, Long-Term Deferred Tax changed N/A year-over-year to $2.0 million; the TTM figure through Sep 2023 stood at $2.0 million (changed N/A YoY), while the FY2023 annual figure was $2.1 million, changed N/A from the prior year.
Long-Term Deferred Tax for Q3 2023 stood at $2.0 million, up from -$27920.0 in the prior quarter.
The five-year high for Long-Term Deferred Tax was $2.0 million in Q3 2023, with the low at -$27920.0 in Q3 2023.
The 3-year median for Long-Term Deferred Tax is $12485.1 (2023), against an average of $674676.5.
The sharpest annual moves came in 2022 and 2023: Long-Term Deferred Tax soared 78173.87% in 2022, then soared 195.75% in 2023.
Immuron's Long-Term Deferred Tax stood at -$2569.4 in 2021, then jumped by 78173.87% to $2.0 million in 2022, then gained by 2.07% to $2.0 million in 2023.
Business Quant data shows IMRN's Long-Term Deferred Tax at $2.0 million in Q3 2023, -$27920.0 in Q3 2023, and $18660.6 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Immuron	6.75 Mn	6.73 Mn	-

Download Data